Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: J Clin Gastroenterol. 2015 Jan;49(1):76–83. doi: 10.1097/MCG.0000000000000055

Table 2.

Patient Characteristics by Global Self-Efficacy Score at Baseline and Treatment Week 24.

Characteristic Baseline Global Self-Efficacy Score (N=384) Week 24 Global Self-Efficacy Score (N=170)

n % Median (IQR) p-value n % Median (IQR) p-value
Gender 0.079 0.316
 Male 248 66 8.8 (7.7–9.6) 101 59 8.4 (7.1–9.4)
 Female 136 34 8.5 (7.8–9.3) 69 41 8.1 (6.7–9.2)
Race 0.768 0.393
 AA 183 48 8.7 (7.8–9.5) 65 38 8.4 (7.2–9.4)
 CA 201 52 8.7 (7.7–9.4) 105 62 8.2 (6.7–9.2)
Marital Status* <0.001 0.003
 Married/Relationship 186 48 9.0 (8.1–9.7) 80 48 8.4 (7.7–9.5)
 Never Married 71 19 8.2 (7.5–9.2) 29 18 8.2 (7.1–9.1)
 Divorced/Widow/Separated 127 33 8.6 (7.5–9.2) 57 34 7.5 (6.5–9.1)
Education Level* 0.043 0.461
 < High School 69 18 8.4 (7.4–9.4) 30 18 7.7 (6.6–9.4)
 ≥ High School 314 82 8.8 (7.9–9.5) 135 82 8.3 (7.0–9.2)
Employment Status* <0.001 <0.001
 Employed 245 64 8.9 (8.2–9.6) 104 63 8.5 (7.4–9.4)
 Unemployed 139 36 8.3 (7.6–9.3) 62 37 7.5 (6.5–8.5)
Insurance* <0.001 0.028
 Private 230 60 8.9 (8.2–9.6) 90 55 8.5 (7.4–9.4)
 Public 85 22 8.2 (7.5–9.2) 34 21 7.4 (6.5–8.4)
 Uninsured 67 18 8.4 (7.3–9.1) 40 24 8.1 (6.6–9.0)

Note: IQR: Interquartile Range. Self-efficacy scores range from 0–10, with higher scores indicative of higher self-efficacy.

*

Sample sizes may not sum to overall N. Three level post-hoc pairwise comparisons analyzed using Kruskal-Wallis test with a Bonferroni correction for multiple comparisons set at 0.05/3=0.0167.